<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093235</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000668530</org_study_id>
    <secondary_id>CRCA-CCTC-WCTU-ARTemis</secondary_id>
    <secondary_id>ISRCTN68502941</secondary_id>
    <secondary_id>EUDRACT-2008-002322-11</secondary_id>
    <secondary_id>EU-21017</secondary_id>
    <secondary_id>MREC-08/H1102/104</secondary_id>
    <nct_id>NCT01093235</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer</brief_title>
  <official_title>ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin&#xD;
      hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as&#xD;
      bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells&#xD;
      to grow and spread. Others find tumor cells and help kill them or carry tumor-killing&#xD;
      substances to them. It is not yet known whether giving combination chemotherapy together with&#xD;
      or without bevacizumab is more effective in treating patients with nonmetastatic breast&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy&#xD;
      works compared with giving combination chemotherapy together with bevacizumab in treating&#xD;
      patients with nonmetastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the efficacy of neoadjuvant therapy comprising docetaxel, fluorouracil,&#xD;
           epirubicin hydrochloride, and cyclophosphamide with versus without bevacizumab in&#xD;
           patients with HER2-negative nonmetastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess quality of life of female patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to age (≤ 50 years&#xD;
      old vs &gt; 50 years old), estrogen receptor status (negative [Allred score 0-2] vs weakly&#xD;
      positive [Allred score 3-5] vs strongly positive [Allred score 6-8]), total tumor size* (≤ 50&#xD;
      mm vs &gt; 50 mm), clinical involvement of axillary nodes (yes vs no), and inflammatory/locally&#xD;
      advanced disease (T4) (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      NOTE: *In cases with multifocal disease in one breast, or bilateral disease, the size to be&#xD;
      used for the stratification is the sum of the single largest diameter of all measurable&#xD;
      tumors.&#xD;
&#xD;
        -  Arm I: Patients receive docetaxel IV on day 1; treatment repeats every 3 weeks for 3&#xD;
           courses. Patients then receive fluorouracil IV, epirubicin hydrochloride IV, and&#xD;
           cyclophosphamide IV on day 1 (FEC). Treatment with fluorouracil, epirubicin&#xD;
           hydrochloride, and cyclophosphamide repeats every 3 weeks for 3 courses.&#xD;
&#xD;
        -  Arm II: Patients receive bevacizumab IV over 30 to 90 minutes and docetaxel IV on day 1;&#xD;
           treatment repeats every 3 weeks for 3 courses. Patients then receive FEC as in arm I.&#xD;
           Treatment with FEC repeats every 3 weeks for 3 courses. Patients also receive&#xD;
           bevacizumab IV over 30 to 90 minutes and docetaxel IV on day 1 in FEC course 1 only.&#xD;
&#xD;
      Within 3-6 weeks after completion of last dose of study therapy, patients in both arms&#xD;
      undergo surgery. Within 4-8 weeks after surgery, patients undergo radiotherapy according to&#xD;
      standard protocol.&#xD;
&#xD;
      Women complete quality-of-life questionnaires (FACT-B and EuroQoL) at baseline and during and&#xD;
      after completion of study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for 2 years and&#xD;
      then annually for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete pathological response rates (tumor and lymph nodes)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate in breast alone</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response after 3 and 6 courses of chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast conservation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities, including cardiac safety and surgical complications (wound healing, bleeding, and thrombosis)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cardiac Toxicity</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
          -  HER2-negative disease&#xD;
&#xD;
               -  IHC 0/1 OR IHC 2+ and FISH negative&#xD;
&#xD;
          -  Must meet 1 of the following criteria:&#xD;
&#xD;
               -  Unifocal tumor meeting 1 of the following criteria:&#xD;
&#xD;
                    -  T2 or T3 tumors (radiological size &gt; 20 mm)&#xD;
&#xD;
                    -  T4 tumor of any size with direct extension to the chest wall or the skin&#xD;
&#xD;
                    -  Inflammatory carcinoma with tumor of any size&#xD;
&#xD;
               -  Multifocal tumor meeting the following criteria:&#xD;
&#xD;
                    -  The sum of each tumors' maximum diameter must be ≥ 20 mm (total radiological&#xD;
                       tumor size ≥ 20 mm)&#xD;
&#xD;
               -  Other locally advanced disease meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Any T stage with involvement of large or fixed axillary lymph nodes&#xD;
                       (radiological diameter &gt; 20 mm or clinical N2) and primary breast tumor of&#xD;
                       any diameter&#xD;
&#xD;
                    -  Any T stage with involvement of large or fixed axillary lymph nodes&#xD;
                       (radiological diameter &gt; 20 mm or clinical N2), without a primary breast&#xD;
                       tumor identified and the presence of breast cancer in a lymph node must be&#xD;
                       histopathologically confirmed by lymph node biopsy (tru-cut or whole lymph&#xD;
                       node)&#xD;
&#xD;
          -  Embedded paraffin tumor block available from pre-chemotherapy biopsy and surgical&#xD;
             specimen&#xD;
&#xD;
          -  Bilateral disease allowed&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  No prior breast cancer except for ductal carcinoma in situ of the breast surgically&#xD;
             cured &gt; 10 years ago&#xD;
&#xD;
          -  Any hormone receptor status&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC &gt; 3 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  AST/ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times ULN&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
               -  Isolated elevation of bilirubin to ≤ 3 times ULN with a presumptive diagnosis of&#xD;
                  Gilbert syndrome allowed if AST/ALT and alkaline phosphatase are within normal&#xD;
                  limits&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  PT and PTT/aPTT ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  Must be fit to receive chemotherapy on this trial, in the opinion of the responsible&#xD;
             clinician, as indicated by the following criteria:&#xD;
&#xD;
               -  No clinically significant cardiac abnormalities&#xD;
&#xD;
               -  No myocardial infarction within the past 6 months&#xD;
&#xD;
               -  LVEF normal (at least 50%) by MUGA scan or echocardiogram&#xD;
&#xD;
          -  No prior ischemic heart disease, cerebrovascular disease, peripheral vascular disease,&#xD;
             arterial or venous thromboembolic disease, cardiac failure, inflammatory bowel&#xD;
             disease, gastroduodenal ulcer, symptomatic diverticulitis, or bleeding diathesis&#xD;
&#xD;
          -  No uncontrolled hypertension (systolic BP &gt; 150 mm Hg or diastolic BP &gt; 90 mm Hg) with&#xD;
             or without antihypertensive medication&#xD;
&#xD;
               -  Patients with initial blood pressure elevations are eligible provided initiation&#xD;
                  or adjustment of antihypertensive medication lowers pressure to meet entry&#xD;
                  criteria&#xD;
&#xD;
          -  No other previous malignancy except basal cell carcinoma, carcinoma in situ of the&#xD;
             cervix, or ductal carcinoma in situ of the breast treated by surgery only and&#xD;
             disease-free for 10 years&#xD;
&#xD;
          -  No concurrent medical or psychiatric problem that might prevent completion of&#xD;
             treatment or follow-up&#xD;
&#xD;
          -  No presence of active uncontrolled infection&#xD;
&#xD;
          -  No history of nephritic or nephrotic syndrome&#xD;
&#xD;
          -  No traumatic injury within the past 28 days&#xD;
&#xD;
          -  No evidence of other disease that, in the opinion of the investigator, places the&#xD;
             patient at high risk of treatment-related complications&#xD;
&#xD;
          -  No nonhealing wound, peptic ulcer, or bone fracture&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior neoadjuvant endocrine therapy&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  No major surgical procedure within the past 28 days&#xD;
&#xD;
          -  No concurrent full therapeutic dose of anticoagulants or aspirin &gt; 325 mg/day,&#xD;
             clopidogrel &gt; 75 mg/day, or corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Earl, MBBS, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1223-336-800</phone>
      <email>Hme22@cam.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>March 24, 2010</last_update_submitted>
  <last_update_submitted_qc>March 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2010</last_update_posted>
  <keyword>cardiac toxicity</keyword>
  <keyword>perioperative/postoperative complications</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>estrogen receptor-negative breast cancer</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-negative breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

